Advertisement
Review Article| Volume 37, ISSUE 6, P1354-1371, June 01, 2015

Download started.

Ok

Evolving Role of Local Anesthetics in Managing Postsurgical Analgesia

      Abstract

      Purpose

      Opioid analgesics, the cornerstone of effective postsurgical pain management, may be associated with risk of opioid-related adverse drug events (ADEs) that may complicate the postsurgical experience. Perioperative multimodal analgesic regimens have the potential to improve postsurgical pain control and may permit use of lower analgesic doses and reduce the incidence of opioid-related ADEs. Utility of traditional local anesthetic formulations to provide analgesia over the entire postsurgical period is limited by their short duration of action. Liposome bupivacaine, a liposomal formulation of bupivacaine indicated for single-dose administration into the surgical site to produce postsurgical analgesia, was evaluated in multiple surgical models as part of multimodal analgesic regimens and was found in clinical trials to provide postsurgical analgesia for up to 72 hours. Here, we provide an overview of the available multimodal analgesic options and recent recommendations for optimal postsurgical pain management.

      Methods

      A review of the literature was conducted, and results from recent clinical trials are included.

      Findings

      The use of a multimodal analgesic regimen, including liposome bupivacaine, can extend the time to first postsurgical opioid use, may reduce postsurgical opioid consumption, and reduce hospital length of stay and costs compared with an opioid-only analgesic regimen.

      Implications

      Use of multimodal analgesic regimens is a practical way to achieve good postsurgical analgesia while minimizing reliance on opioids and associated adverse events. Taken as a whole, evidence from the clinical studies of liposome bupivacaine suggests this local anesthetic formulation may be a useful component of multimodal analgesic regimens for managing postsurgical pain in select patients, with the potential to reduce opioid use and opioid-related ADEs in the postsurgical setting. As with bupivacaine, appropriate use of liposome bupivacaine to optimize clinical effects, economic implications, and patient tolerability will depend on appropriate patient selection, practitioner training, and institutional protocols. As a component of a multimodal analgesic regimen, liposome bupivacaine represents a new approach to extending the duration of postsurgical analgesia. Further studies across a range of surgical settings should help clarify the most appropriate roles for this prolonged-release formulation of bupivacaine.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Adamson R.T.
        • Lew I.
        • Beyzarov E.
        • et al.
        Clinical and economic impact of intra- and postoperative use of opioids and analgesic devices.
        Hosp Pharm. 2011; 46: S1-S3
        • Apfelbaum J.L.
        • Chen C.
        • Mehta S.S.
        • et al.
        Postoperative pain experience: results from a national survey suggest postoperative pain continues to be undermanaged.
        Anesth Analg. 2003; 97: 534-540
        • Clinicians’ quick reference guide to postoperative pain management in adults
        Pain Management Guideline Panel. Agency for Health Care Policy and Research, US Department of Health and Human Services.
        J Pain Symptom Manage. 1992; 7: 214-228
        • Practice guidelines for acute pain management in the perioperative setting
        A report by the American Society of Anesthesiologists Task Force on Pain Management, Acute Pain Section.
        Anesthesiology. 1995; 82: 1071-1081
      1. Practice guidelines for acute pain management in the perioperative setting: an updated report by the American Society of Anesthesiologists Task Force on Acute Pain Management.
        Anesthesiology. 2004; 100: 1573-1581
        • American Society of Anesthesiologists Task Force on Acute Pain Management
        Practice guidelines for acute pain management in the perioperative setting: an updated report by the American Society of Anesthesiologists Task Force on Acute Pain Management.
        Anesthesiology. 2012; 116: 248-273
      2. Geriatrics and Extended Care Strategic Healthcare Group, National Pain Management Coordinating Committee. Pain as the 5th Vital Sign Toolkit. Veterans Health Administration. Department of Veterans Affairs website. http://www.va.gov/painmanagement/docs/toolkit.pdf. Accessed September 18, 2014.

        • Phillips D.M.
        JCAHO pain management standards are unveiled. Joint Commission on Accreditation of Healthcare Organizations.
        JAMA. 2000; 284: 428-429
      3. The Joint Commission. Facts about pain management, 2012. http://www.jointcommission.org/pain_management/. Accessed September 18, 2014.

      4. HCAHPS fact sheet (CAHPS hospital survey), 2012. Centers for Medicare & Medicaid Services, Agency for Healthcare Research and Quality. Hospital Consumer Assessment of Healthcare Providers and Systems. http://www.hcahpsonline.org/files/HCAHPS%20Fact%20Sheet%20May%202012.pdf. Accessed September 18, 2014.

        • Wu C.L.
        • Raja S.N.
        Treatment of acute postoperative pain.
        Lancet. 2011; 377: 2215-2225
        • Warfield C.A.
        • Kahn C.H.
        Acute pain management. Programs in U.S. hospitals and experiences and attitudes among U.S. adults.
        Anesthesiology. 1995; 83: 1090-1094
        • Gan T.J.
        • Habib A.S.
        • Miller T.E.
        • et al.
        Incidence, patient satisfaction, and perceptions of post-surgical pain: results from a US national survey.
        Curr Med Res Opin. 2014; 30: 149-160
        • Dahl J.B.
        • Kehlet H.
        Non-steroidal anti-inflammatory drugs: rationale for use in severe postoperative pain.
        Br J Anaesth. 1991; 66: 703-712
        • White P.F.
        The role of non-opioid analgesic techniques in the management of pain after ambulatory surgery.
        Anesth Analg. 2002; 94: 577-585
        • Kehlet H.
        • Dahl J.B.
        The value of “multimodal” or “balanced analgesia” in postoperative pain treatment.
        Anesth Analg. 1993; 77: 1048-1056
        • Graham G.G.
        • Scott K.F.
        Mechanism of action of paracetamol.
        Am J Ther. 2005; 12: 46-55
        • Aronoff D.M.
        • Oates J.A.
        • Boutaud O.
        New insights into the mechanism of action of acetaminophen: its clinical pharmacologic characteristics reflect its inhibition of the two prostaglandin H2 synthases.
        Clin Pharmacol Ther. 2006; 79: 9-19
        • Taylor C.P.
        Meeting report: the biology and pharmacology of calcium channel α2-δ proteins. Pfizer Satellite Symposium to the 2003 Society for Neuroscience Meeting, Sheraton New Orleans Hotel, New Orleans, LA November 10, 2003.
        CNS Drug Rev. 2004; 10: 183-188
        • Beydoun A.
        • Backonja M.M.
        Mechanistic stratification of antineuralgic agents.
        J Pain Symptom Manage. 2003; 25: S18-S30
        • White P.F.
        The changing role of non-opioid analgesic techniques in the management of postoperative pain.
        Anesth Analg. 2005; 101: S5-S22
        • Joly V.
        • Richebe P.
        • Guignard B.
        • et al.
        Remifentanil-induced postoperative hyperalgesia and its prevention with small-dose ketamine.
        Anesthesiology. 2005; 103: 147-155
      5. The Management of Postoperative Pain Working Group. VHA/DoD clinical practice guideline for the management of postoperative pain, 2002. Veterans Health Administration; Department of Defense. US Department of Veterans Affairs. http://www.healthquality.va.gov. Accessed September 18, 2014.

        • Oderda G.M.
        • Said Q.
        • Evans R.S.
        • et al.
        Opioid-related adverse drug events in surgical hospitalizations: impact on costs and length of stay.
        Ann Pharmacother. 2007; 41: 400-407
        • Souter A.J.
        • Fredman B.
        • White P.F.
        Controversies in the perioperative use of nonsterodial antiinflammatory drugs.
        Anesth Analg. 1994; 79: 1178-1190
        • Wheeler M.
        • Oderda G.M.
        • Ashburn M.A.
        • et al.
        Adverse events associated with postoperative opioid analgesia: a systematic review.
        J Pain. 2002; 3: 159-180
        • Hutchison R.W.
        Challenges in acute post-operative pain management.
        Am J Health Syst Pharm. 2007; 64: S2-S5
        • Grissinger M.
        Results of the opioid knowledge assessment from the PA Hospital Engagement Network Adverse Drug Event Collaboration.
        Pa Patient Saf Advis. 2013; 10: 19-26
        • Goettsch W.G.
        • Sukel M.P.
        • van der Peet D.L.
        • et al.
        In-hospital use of opioids increases rate of coded postoperative paralytic ileus.
        Pharmacoepidemiol Drug Saf. 2007; 16: 668-674
        • Senagore A.J.
        Pathogenesis and clinical and economic consequences of postoperative ileus.
        Am J Health Syst Pharm. 2007; 64: S3-S7
        • Craft J.
        Patient-controlled analgesia: is it worth the painful prescribing process?.
        Proc (Bayl Univ Med Cent). 2010; 23: 434-438
        • Hudcova J.
        • McNicol E.
        • Quah C.
        • et al.
        Patient controlled opioid analgesia versus conventional opioid analgesia for postoperative pain.
        Cochrane Database Syst Rev. 2006; : CD003348
        • Adamson R.T.
        • Lew I.
        • Beyzarov E.
        • et al.
        Clinical and economic implications of postsurgical use of opioid therapy.
        Hosp Pharm. 2011; 46: S4-S11
        • Schein J.R.
        • Hicks R.W.
        • Nelson W.W.
        • et al.
        Patient-controlled analgesia-related medication errors in the postoperative period: causes and prevention.
        Drug Saf. 2009; 32: 549-559
        • Grass J.A.
        Patient-controlled analgesia.
        Anesth Analg. 2005; 101: S44-S61
      6. Safe use of opioids in hospitals.
        Sentinel Event Alert. 2012; 49: 1-5
        • Prewitt J.
        • Schneider S.
        • Horvath M.
        • et al.
        PCA safety data review after clinical decision support and smart pump technology implementation.
        J Patient Saf. 2013; 9: 103-109
      7. Hamilton TE. Requirements for hospital medication administration, particularly intravenous (IV) medications and post-operative care of patients receiving IV opioids. Memo 14-15-Hospital. Department of Health & Human Services; Centers for Medicare & Medicaid Services. http://www.cms.gov/Medicare/Provider-Enrollment-and-Certification/SurveyCertificationGenInfo/Downloads/Survey-and-Cert-Letter-14-15.pdf. Accessed June 3, 2014.

        • Covino B.G.
        • Wildsmith J.A.
        Clinical pharmacology of local anesthetic agents.
        in: Cousins M.J. Bridenbaugh P.O. Neural Blockade in Clinical Anesthesia and Management of Pain. 3rd ed. Lippincott-Raven, Philadelphia, Pa1998: 97-128
        • Neal J.M.
        • Bernards C.M.
        • Butterworth 4th, J.F.
        • et al.
        ASRA practice advisory on local anesthetic systemic toxicity.
        Reg Anesth Pain Med. 2010; 35: 152-161
        • Hansen B.P.
        • Beck C.L.
        • Beck E.P.
        • et al.
        Postarthroscopic glenohumeral chondrolysis.
        Am J Sports Med. 2007; 35: 1628-1634
        • Guay J.
        Methemoglobinemia related to local anesthetics: a summary of 242 episodes.
        Anesth Analg. 2009; 108: 837-845
        • D’Angelo R.
        Are the new local anesthetics worth their cost?.
        Acta Anaesthesiol Scand. 2000; 44: 639-641
        • Graham D.J.
        • Campen D.
        • Hui R.
        • et al.
        Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study.
        Lancet. 2005; 365: 475-481
        • Young D.
        FDA labors over NSAID decisions: panel suggests COX-2 inhibitors stay available.
        Am J Health Syst Pharm. 2005; 62: 668-672
        • Pountos I.
        • Georgouli T.
        • Calori G.M.
        • et al.
        Do nonsteroidal anti-inflammatory drugs affect bone healing? A critical analysis.
        ScientificWorldJournal. 2012; 2012: 606404
        • Chan A.T.
        • Manson J.E.
        • Albert C.M.
        • et al.
        Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events.
        Circulation. 2006; 113: 1578-1587
      8. U.S. Food and Drug Administration. Acetaminophen overdose and liver injury - background and options for reducing injury. Food and Drug Administration website. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/DrugSafetyandRiskManagementAdvisoryCommittee/UCM164897.pdf. Accessed September 2, 2014.

        • Forget P.
        • Wittebole X.
        • Laterre P.F.
        Therapeutic dose of acetaminophen may induce fulminant hepatitis in the presence of risk factors: a report of two cases.
        Br J Anaesth. 2009; 103: 899-900
      9. U.S. Food and Drug Administration. FDA Drug Safety Communication: prescription acetaminophen products to be limited to 325 mg per dosage unit; boxed warning will highlight potential for severe liver failure. Food and Drug Administration website. http://www.fda.gov/drugs/drugsafety/ucm239821.htm. Accessed September 2, 2014.

      10. U.S. Food and Drug Administration. FDA warns of rare acetaminophen risk. FDA Consumer Health Information. Food and Drug Administration website. http://www.fda.gov/downloads/ForConsumers/ConsumerUpdates/UCM363067.pdf. Accessed September 2, 2014.

        • Pasero C.
        • Stannard D.
        The role of intravenous acetaminophen in acute pain management: a case-illustrated review.
        Pain Manag Nurs. 2012; 13: 107-124
        • Jahr J.S.
        • Lee V.K.
        Intravenous acetaminophen.
        Anesthesiol Clin. 2010; 28: 619-645
        • White P.F.
        • Way W.L.
        • Trevor A.J.
        Ketamine--its pharmacology and therapeutic uses.
        Anesthesiology. 1982; 56: 119-136
        • Kohrs R.
        • Durieux M.E.
        Ketamine: teaching an old drug new tricks.
        Anesth Analg. 1998; 87: 1186-1193
        • Dworkin R.H.
        • O’Connor A.B.
        • Backonja M.
        • et al.
        Pharmacologic management of neuropathic pain: evidence-based recommendations.
        Pain. 2007; 132: 237-251
        • Lazarou J.
        • Pomeranz B.H.
        • Corey P.N.
        Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies.
        JAMA. 1998; 279: 1200-1205
        • Classen D.C.
        • Resar R.
        • Griffin F.
        • et al.
        ‘Global trigger tool’ shows that adverse events in hospitals may be ten times greater than previously measured.
        Health Aff (Millwood). 2011; 30: 581-589
        • Bates D.W.
        • Spell N.
        • Cullen D.J.
        • et al.
        The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group.
        JAMA. 1997; 277: 307-311
        • Classen D.C.
        • Pestotnik S.L.
        • Evans R.S.
        • et al.
        Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality.
        JAMA. 1997; 277: 301-306
        • Oderda G.M.
        • Evans R.S.
        • Lloyd J.
        • et al.
        Cost of opioid-related adverse drug events in surgical patients.
        J Pain Symptom Manage. 2003; 25: 276-283
        • Oderda G.
        Challenges in the management of acute postsurgical pain.
        Pharmacotherapy. 2012; 32: 6S-11S
        • Oderda G.M.
        • Gan T.J.
        • Johnson B.H.
        • et al.
        Effect of opioid-related adverse events on outcomes in selected surgical patients.
        J Pain Palliat Care Pharmacother. 2013; 27: 62-70
        • Zhao S.Z.
        • Chung F.
        • Hanna D.B.
        • et al.
        Dose-response relationship between opioid use and adverse effects after ambulatory surgery.
        J Pain Symptom Manage. 2004; 28: 35-46
        • Goldstein J.L.
        • Matuszewski K.A.
        • Delaney C.P.
        • et al.
        Inpatient economic burden of postoperative ileus associated with abdominal surgery in the United States.
        P&T. 2007; 32: 82-90
        • Kehlet H.
        Surgical stress: the role of pain and analgesia.
        Br J Anaesth. 1989; 63: 189-195
        • Oderda G.
        New direction in the management of postsurgical pain. Introduction.
        Pharmacotherapy. 2012; 32: 1S-5S
        • White P.F.
        Multimodal analgesia: its role in preventing postoperative pain.
        Curr Opin Investig Drugs. 2008; 9: 76-82
        • White P.F.
        • Kehlet H.
        • Neal J.M.
        • et al.
        The role of the anesthesiologist in fast-track surgery: from multimodal analgesia to perioperative medical care.
        Anesth Analg. 2007; 104: 1380-1396
        • Maund E.
        • McDaid C.
        • Rice S.
        • et al.
        Paracetamol and selective and non-selective non-steroidal anti-inflammatory drugs for the reduction in morphine-related side-effects after major surgery: a systematic review.
        Br J Anaesth. 2011; 106: 292-297
      11. Dasta J. Local anesthetics: evolving to a new standard of care. Pharm Pract News Special Report. January 2013:1-8.

        • Thomas J.M.
        • Schug S.A.
        Recent advances in the pharmacokinetics of local anaesthetics. Long-acting amide enantiomers and continuous infusions.
        Clin Pharmacokinet. 1999; 36: 67-83
        • Tucker G.T.
        • Mather L.E.
        Properties, absorption, and disposition of local anesthetic agents.
        in: Cousins M.J. Bridenbaugh P.O. Neural Blockade in Clinical Anesthesia and Management of Pain. 3rd ed. Lippincott-Raven Publishers, Philadelphia, Pa1998: 55-95
        • Jirasiritham S.
        • Tantivitayatan K.
        • Jirasiritham S.
        Perianal blockage with 0.5% bupivacaine for postoperative pain relief in hemorrhoidectomy.
        J Med Assoc Thai. 2004; 87: 660-664
        • Chester J.F.
        • Stanford B.J.
        • Gazet J.C.
        Analgesic benefit of locally injected bupivacaine after hemorrhoidectomy.
        Dis Colon Rectum. 1990; 33: 487-489
        • Moiniche S.
        • Mikkelsen S.
        • Wetterslev J.
        • et al.
        A qualitative systematic review of incisional local anaesthesia for postoperative pain relief after abdominal operations.
        Br J Anaesth. 1998; 81: 377-383
        • Knudsen K.
        • Beckman Suurkula M.
        • Blomberg S.
        • et al.
        Central nervous and cardiovascular effects of i.v. infusions of ropivacaine, bupivacaine and placebo in volunteers.
        Br J Anaesth. 1997; 78: 507-514
        • Bardsley H.
        • Gristwood R.
        • Baker H.
        • et al.
        A comparison of the cardiovascular effects of levobupivacaine and rac-bupivacaine following intravenous administration to healthy volunteers.
        Br J Clin Pharmacol. 1998; 46: 245-249
        • Jorfeldt L.
        • Lofstrom B.
        • Pernow B.
        • et al.
        The effect of local anaesthetics on the central circulation and respiration in man and dog.
        Acta Anaesthesiol Scand. 1968; 12: 153-169
        • Scott D.B.
        • Lee A.
        • Fagan D.
        • et al.
        Acute toxicity of ropivacaine compared with that of bupivacaine.
        Anesth Analg. 1989; 69: 563-569
        • Beilin Y.
        • Halpern S.
        Focused review: ropivacaine versus bupivacaine for epidural labor analgesia.
        Anesth Analg. 2010; 111: 482-487
        • Heavner J.E.
        Local anesthetics.
        Curr Opin Anaesthesiol. 2007; 20: 336-342
        • Lipfert P.
        • Seitz R.J.
        • Arndt J.O.
        Ultralong-lasting nerve block: triethyldodecyl ammonium bromide is probably a neurotoxin rather than a local anesthetic.
        Anesthesiology. 1987; 67: 896-904
        • McCartney C.J.
        • Duggan E.
        • Apatu E.
        Should we add clonidine to local anesthetic for peripheral nerve blockade? A qualitative systematic review of the literature.
        Reg Anesth Pain Med. 2007; 32: 330-338
        • Ilfeld B.M.
        • Enneking F.K.
        Continuous peripheral nerve blocks at home: a review.
        Anesth Analg. 2005; 100: 1822-1833
        • Barber F.A.
        • Herbert M.A.
        The effectiveness of an anesthetic continuous-infusion device on postoperative pain control.
        Arthroscopy. 2002; 18: 76-81
        • Kryger Z.B.
        • Rawlani V.
        • Lu L.
        • et al.
        Decreased postoperative pain, narcotic, and antiemetic use after breast reduction using a local anesthetic pain pump.
        Ann Plast Surg. 2008; 61: 147-152
        • Singh K.
        • Phillips F.M.
        • Kuo E.
        • et al.
        A prospective, randomized, double-blind study of the efficacy of postoperative continuous local anesthetic infusion at the iliac crest bone graft site after posterior spinal arthrodesis: a minimum of 4-year follow-up.
        Spine (Phila Pa 1976). 2007; 32: 2790-2796
        • Lu L.
        • Fine N.A.
        The efficacy of continuous local anesthetic infiltration in breast surgery: reduction mammaplasty and reconstruction.
        Plast Reconstr Surg. 2005; 115: 1927-1934
        • Sanchez B.
        • Waxman K.
        • Tatevossian R.
        • et al.
        Local anesthetic infusion pumps improve postoperative pain after inguinal hernia repair: a randomized trial.
        Am Surg. 2004; 70: 1002-1006
        • White P.F.
        • Rawal S.
        • Latham P.
        • et al.
        Use of a continuous local anesthetic infusion for pain management after median sternotomy.
        Anesthesiology. 2003; 99: 918-923
        • Liu S.S.
        • Richman J.M.
        • Thirlby R.C.
        • et al.
        Efficacy of continuous wound catheters delivering local anesthetic for postoperative analgesia: a quantitative and qualitative systematic review of randomized controlled trials.
        J Am Coll Surg. 2006; 203: 914-932
        • Dowling R.
        • Thielmeier K.
        • Ghaly A.
        • et al.
        Improved pain control after cardiac surgery: results of a randomized, double-blind, clinical trial.
        J Thorac Cardiovasc Surg. 2003; 126: 1271-1278
        • Bianconi M.
        • Ferraro L.
        • Traina G.C.
        • et al.
        Pharmacokinetics and efficacy of ropivacaine continuous wound instillation after joint replacement surgery.
        Br J Anaesth. 2003; 91: 830-835
        • Bianconi M.
        • Ferraro L.
        • Ricci R.
        • et al.
        The pharmacokinetics and efficacy of ropivacaine continuous wound instillation after spine fusion surgery.
        Anesth Analg. 2004; 98: 166-172
        • Yoost T.R.
        • McIntyre M.
        • Savage S.J.
        Continuous infusion of local anesthetic decreases narcotic use and length of hospitalization after laparoscopic renal surgery.
        J Endourol. 2009; 23: 623-626
        • Heller L.
        • Kowalski A.M.
        • Wei C.
        • et al.
        Prospective, randomized, double-blind trial of local anesthetic infusion and intravenous narcotic patient-controlled anesthesia pump for pain management after free TRAM flap breast reconstruction.
        Plast Reconstr Surg. 2008; 122: 1010-1018
        • Schurr M.J.
        • Gordon D.B.
        • Pellino T.A.
        • et al.
        Continuous local anesthetic infusion for pain management after outpatient inguinal herniorrhaphy.
        Surgery. 2004; 136: 761-769
        • Bray Jr, D.A.
        • Nguyen J.
        • Craig J.
        • et al.
        Efficacy of a local anesthetic pain pump in abdominoplasty.
        Plast Reconstr Surg. 2007; 119: 1054-1059
        • Kazmier F.R.
        • Henry S.L.
        • Christiansen D.
        • et al.
        A prospective, randomized, double-blind, controlled trial of continuous local anesthetic infusion in cosmetic breast augmentation.
        Plast Reconstr Surg. 2008; 121: 711-715
        • Webb D.
        • Guttmann D.
        • Cawley P.
        • et al.
        Continuous infusion of a local anesthetic versus interscalene block for postoperative pain control after arthroscopic shoulder surgery.
        Arthroscopy. 2007; 23: 1006-1011
        • Polglase A.L.
        • McMurrick P.J.
        • Simpson P.J.
        • et al.
        Continuous wound infusion of local anesthetic for the control of pain after elective abdominal colorectal surgery.
        Dis Colon Rectum. 2007; 50: 2158-2167
        • Hoeft M.A.
        • Rathmell J.P.
        • Dayton M.R.
        • et al.
        Continuous, intra-articular infusion of bupivacaine after total-knee arthroplasty may lead to potentially toxic serum levels of local anesthetic.
        Reg Anesth Pain Med. 2005; 30: 414-415
        • Tilleul P.
        • Aissou M.
        • Bocquet F.
        • et al.
        Cost-effectiveness analysis comparing epidural, patient-controlled intravenous morphine, and continuous wound infiltration for postoperative pain management after open abdominal surgery.
        Br J Anaesth. 2012; 108: 998-1005
        • Aguirre J.
        • Del Moral A.
        • Cobo I.
        • et al.
        The role of continuous peripheral nerve blocks.
        Anesthesiol Res Pract. 2012; 2012: 560879
        • Pepin J.L.
        • Dasta J.F.
        • New M
        Ensuring safe and economical use of elastomeric infusion devices [letter].
        Am J Health Syst Pharm. 2011; 68: 2330-2331
        • Birrer K.L.
        • Anderson R.L.
        • Liu-DeRyke X.
        • et al.
        Measures to improve safety of an elastomeric infusion system for pain management.
        Am J Health Syst Pharm. 2011; 68: 1251-1255
      12. U.S. Food and Drug Administration. Information for healthcare professionals: chondrolysis reported with continuously infused local anesthetics (marketed as bupivacaine, chlorprocaine, lidocaine, mepivacaine, procaine and ropivacaine). Food and Drug Administration website. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm190302.htm. Accessed September 2, 2014.

        • Brown S.L.
        • Morrison A.E.
        Local anesthetic infusion pump systems adverse events reported to the Food and Drug Administration.
        Anesthesiology. 2004; 100: 1305-1307
        • Massaro F.
        Liposomal bupivacaine: a long-acting local anesthetic for postsurgical analgesia.
        Formulary. 2012; 47: 212-226
        • Noyes F.R.
        • Fleckenstein C.M.
        • Barber-Westin S.D.
        The development of postoperative knee chondrolysis after intra-articular pain pump infusion of an anesthetic medication: a series of twenty-one cases.
        J Bone Joint Surg Am. 2012; 94: 1448-1457
        • Scott N.B.
        Wound infiltration for surgery.
        Anaesthesia. 2010; 65: 67-75
        • Kerr D.R.
        • Kohan L.
        Local infiltration analgesia: a technique for the control of acute postoperative pain following knee and hip surgery: a case study of 325 patients.
        Acta Orthop. 2008; 79: 174-183
        • Sinatra R.S.
        • Torres J.
        • Bustos A.M.
        Pain management after major orthopaedic surgery: current strategies and new concepts.
        J Am Acad Orthop Surg. 2002; 10: 117-129
        • Fassoulaki A.
        • Triga A.
        • Melemeni A.
        • et al.
        Multimodal analgesia with gabapentin and local anesthetics prevents acute and chronic pain after breast surgery for cancer.
        Anesth Analg. 2005; 101: 1427-1432
        • Pluijms W.A.
        • Steegers M.A.
        • Verhagen A.F.
        • et al.
        Chronic post-thoracotomy pain: a retrospective study.
        Acta Anaesthesiol Scand. 2006; 50: 804-808
        • Poleshuck E.L.
        • Katz J.
        • Andrus C.H.
        • et al.
        Risk factors for chronic pain following breast cancer surgery: a prospective study.
        J Pain. 2006; 7: 626-634
      13. Exparel [prescribing information]. Parsippany, NJ: Pacira Pharmaceuticals, Inc.; 2014.

      14. Langford RM, Chappell GM, Karrasch JA. A single administration of DepoBupivacaine intraoperatively results in prolonged detectable plasma bupivacaine and analgesia in patients undergoing inguinal hernia repair [abstract P-9088]. Abstract presented at: Annual Postgraduate Assembly in Anesthesiology of the New York State Society of Anesthesiologists; December 12-16, 2008; New York, NY.

        • White P.F.
        • Schooley G.
        • Ardeleanu M.
        Analgesia following a single administration of depobupivacaine intraoperatively in patients undergoing inguinal herniorrhaphy: preliminary dose-ranging studies [abstract S-242].
        Anesth Analg. 2009; 108 (S-242)
        • Bramlett K.
        • Onel E.
        • Viscusi E.R.
        • et al.
        A randomized, double-blind, dose-ranging study comparing wound infiltration of DepoFoam bupivacaine, an extended-release liposomal bupivacaine, to bupivacaine HCl for postsurgical analgesia in total knee arthroplasty.
        Knee. 2012; 19: 530-536
        • Haas E.
        • Onel E.
        • Miller H.
        • et al.
        A double-blind, randomized, active-controlled study for post-hemorrhoidectomy pain management with liposome bupivacaine, a novel local analgesic formulation.
        Am Surg. 2012; 78: 574-581
        • Gorfine S.R.
        • Onel E.
        • Patou G.
        • et al.
        Bupivacaine extended-release liposome injection for prolonged postsurgical analgesia in patients undergoing hemorrhoidectomy: a multicenter, randomized, double-blind, placebo-controlled trial.
        Dis Colon Rectum. 2011; 54: 1552-1559
        • Smoot J.D.
        • Bergese S.D.
        • Onel E.
        • et al.
        The efficacy and safety of DepoFoam bupivacaine in patients undergoing bilateral, cosmetic, submuscular augmentation mammoplasty: a randomized, double-blind, active-control study.
        Aesthet Surg J. 2012; 32: 69-76
        • Golf M.
        • Daniels S.E.
        • Onel E.
        A phase 3, randomized, placebo-controlled trial of DepoFoam(R) bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy.
        Adv Ther. 2011; 28: 776-788
        • Cohen S.M.
        Extended pain relief trial utilizing infiltration of Exparel®, a long-acting multivesicular liposome formulation of bupivacaine: a Phase IV health economic trial in adult patients undergoing open colectomy.
        J Pain Res. 2012; 5: 567-572
        • Marcet J.E.
        • Nfonsam V.N.
        • Larach S.
        An extended paIn relief trial utilizing the infiltration of a long-acting Multivesicular liPosome foRmulation Of bupiVacaine, EXPAREL (IMPROVE): a Phase IV health economic trial in adult patients undergoing ileostomy reversal.
        J Pain Res. 2013; 6: 549-555
        • Vogel J.D.
        Liposome bupivacaine (EXPAREL®) for extended pain relief in patients undergoing ileostomy reversal at a single institution with a fast-track discharge protocol: an IMPROVE Phase IV health economics trial.
        J Pain Res. 2013; 6: 605-610
      15. Sternlicht A, Shapiro M, Robelen G, et al. Initial findings using EXPAREL® (bupivacaine liposome injectable suspension) via infiltration into the transversus abdominis plane (TAP) for postsurgical analgesia in robotic prostatectomy (RP). Abstract presented at: Annual Fall Pain Meeting and Workshops of the American Society of Regional Anesthesia and Pain Medicine; November 15-18, 2012; Miami Beach, Fl.

      16. Feierman DE, Kronenfeld M, Gupta PM, et al. Evaluation of Exparel® use via infiltration into the transversus abdominis plane for prolonged postoperative analgesia in subjects undergoing open abdominal hernia repair. Poster presented at: Annual Meeting of the International Anesthesia Research Society; May 4-7, 2013; San Diego, Ca.

      17. Data on file. Unpublished results. Parsippany, NJ: Pacira Pharmaceuticals, Inc.; 2011.

        • Hu D.
        • Onel E.
        • Singla N.
        • et al.
        Pharmacokinetic profile of liposome bupivacaine injection following a single administration at the surgical site.
        Clin Drug Investig. 2013; 33: 109-115
        • Bergese S.D.
        • Ramamoorthy S.
        • Patou G.
        • et al.
        Efficacy profile of liposome bupivacaine, a novel formulation of bupivacaine for postsurgical analgesia.
        J Pain Res. 2012; 5: 107-116
        • Viscusi E.R.
        • Sinatra R.
        • Onel E.
        • et al.
        The safety of liposome bupivacaine, a novel local analgesic formulation.
        Clin J Pain. 2014; 30: 102-110
        • Dasta J.
        • Ramamoorthy S.
        • Patou G.
        • et al.
        Bupivacaine liposome injectable suspension compared with bupivacaine HCl for the reduction of opioid burden in the postsurgical setting.
        Curr Med Res Opin. 2012; 28: 1609-1615
      18. Avinza [package insert]. Bristol, Tn: King Pharmaceuticals, Inc; 2013.

        • Candiotti K.A.
        • Sands L.R.
        • Lee E.
        • et al.
        Liposome bupivacaine for postsurgical analgesia in adult patients undergoing laparoscopic colectomy: results from prospective phase IV sequential cohort studies assessing health economic outcomes.
        Curr Ther Res. 2014; 76: 1-6
        • Barrington J.W.
        • Dalury D.F.
        • Emerson Jr, R.H.
        • et al.
        Improving patient outcomes through advanced pain management techniques in total hip and knee arthroplasty.
        Am J Orthoped (Belle Mead NJ). 2013; 42: S1-S17
      19. Sternlicht A, Shapiro M, Robelen G, et al. Initial findings using EXPAREL® (bupivacaine liposome injectable suspension) via infiltration into the transversus abdominis plane for postsurgical analgesia in robotic prostatectomy. Poster presented at: Annual Fall Pain Meeting and Workshops of the American Society of Regional Anesthesia and Pain Medicine; November 15-18, 2012; Miami Beach, Fl.

        • Richard B.M.
        • Newton P.
        • Ott L.R.
        • et al.
        The safety of EXPAREL® (bupivacaine liposome injectable suspension) administered by peripheral nerve block in rabbits and dogs.
        J Drug Deliv. 2012; 2012 ([epub]): 962101
        • Ilfeld B.M.
        • Malhotra N.
        • Furnish T.J.
        • et al.
        Liposomal bupivacaine as a single-injection peripheral nerve block: a dose-response study.
        Anesth Analg. 2013; 117: 1248-1256
        • Viscusi E.R.
        • Candiotti K.A.
        • Onel E.
        • et al.
        The pharmacokinetics and pharmacodynamics of liposome bupivacaine administered via a single epidural injection to healthy volunteers.
        Reg Anesth Pain Med. 2012; 37: 616-622
        • Kharitonov V.
        A review of the compatibility of liposome bupivacaine with other drug products and commonly used implant materials.
        Postgrad Med. 2014; 126: 129-138
        • Bergese S.D.
        • Onel E.
        • Morren M.
        • et al.
        Bupivacaine extended-release liposome injection exhibits a favorable cardiac safety profile.
        Reg Anesth Pain Med. 2012; 37: 145-151
        • Mulroy M.F.
        Systemic toxicity and cardiotoxicity from local anesthetics: incidence and preventive measures.
        Reg Anesth Pain Med. 2002; 27: 556-561
      20. Marcaine [package insert]. Sodertalje, Sweden: AstraZeneca; 2010.

        • Baxter R.
        • Bramlett K.
        • Onel E.
        • et al.
        Impact of local administration of liposome bupivacaine for postsurgical analgesia on wound healing: a review of data from ten prospective, controlled clinical studies.
        Clin Ther. 2013; 35: 312-320
        • Pepin J.
        • Wright R.
        Cost trade-off analysis of bupivacaine liposome injectable suspension in a community hospital setting [abstract 260].
        Pharmacotherapy. 2013; 33: e260